SCHEMBL3363508

SCHEMBL3363508

CN1CCCN(C(=O)c2ccc(-c3ccc(/C=C4/SC(=O)NC4=O)o3)cc2)CC1

nearest known ligand 0.58

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PIK3CG P48736 7/20 0.58
PIK3CA P42336 3/20 0.58
IGF1R P08069 5/20 0.55
PIM1 P11309 3/20 0.52
PIM2 Q9P1W9 3/20 0.52
FLT3 P36888 1/20 0.52
PIM3 Q86V86 1/20 0.52
CDK2 P24941 3/20 0.52
INSR P06213 3/20 0.52
MEN1 O00255 1/20 0.52
POLB P06746 1/20 0.52
AHR P35869 1/20 0.52
KMT2A Q03164 1/20 0.52
HSPD1 P10809 1/20 0.51
HSPE1 P61604 1/20 0.51
TTR P02766 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12989755 1.00 PIK3CG (0.58) PIK3CGPIK3CAIGF1RPIM1PIM2
SCHEMBL3363515 1.00 PIK3CG (0.58) PIK3CGPIK3CAIGF1RPIM1PIM2
SCHEMBL3362155 0.92 IGF1R (0.64) PIK3CGPIK3CAIGF1RPIM1PIM2
SCHEMBL12990051 0.92 IGF1R (0.64) PIK3CGPIK3CAIGF1RPIM1PIM2
SCHEMBL3362150 0.92 IGF1R (0.64) PIK3CGPIK3CAIGF1RPIM1PIM2
SCHEMBL3363321 0.89 PIM1 (0.66) PIK3CGPIK3CAIGF1RPIM1PIM2
SCHEMBL12990481 0.89 PIM1 (0.66) PIK3CGPIK3CAIGF1RPIM1PIM2
SCHEMBL3363324 0.89 PIM1 (0.66) PIK3CGPIK3CAIGF1RPIM1PIM2
SCHEMBL3363524 0.87 IGF1R (0.69) PIK3CGPIK3CAIGF1RPIM1PIM2
SCHEMBL12990054 0.87 IGF1R (0.69) PIK3CGPIK3CAIGF1RPIM1PIM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100331315-A1 RHODANINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS SENHWA BIOSCIENCES, INC. (TW) 2010-12-30 US disclosed
US-20100331315-A1 RHODANINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS SENHWA BIOSCIENCES, INC. (TW) 2010-12-30 US disclosed
US-20100331315-A1 RHODANINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS SENHWA BIOSCIENCES, INC. (TW) 2010-12-30 US disclosed
WO-2010148351-A1 RHODANINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS CYLENE PHARMACEUTICALS, INC. (US) 2010-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100331315-A1 RHODANINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS PIM2, PIM1, CDK2 PIK3CG 456/4885PIK3CA 496/4885IGF1R 522/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.